Effect of allopurinol (4-Hydroxypyrazolo-(3,4-d)pyrimidine) on serum and urinary uric acid in primary and secondary gout

Robins, 1956, Potential purine antagonists. I. Synthesis of some 4,6-substituted pyrazolo(3,4-d)-pyrimidines, J. Am. Chem. Soc., 78, 784, 10.1021/ja01585a023

Falco, 1956, Studies on condensed pyrimidine systems. XV. Some pyrazolo(3,4-d)pyrimidines, J. Am. Chem. Soc., 78, 3143, 10.1021/ja01594a046

Skipper, 1957, Structure-activity relationships observed on screening a series of pyrazolopyrimidines against experimental neoplasms, Cancer Res., 17, 579

Shaw, 1960, Studies with the experimental antitumor agent 4-aminopyrazolo- (3,4-d)pyrimidine, Cancer, 13, 482, 10.1002/1097-0142(196005/06)13:3<482::AID-CNCR2820130310>3.0.CO;2-S

Lorz, 1950, Specificity of xanthine oxidase, 9, 197

Feigelson, 1957, Pyrazolopyrimidines as inhibitors and substrates of xanthine oxidase, J. Biol. Chem., 226, 993, 10.1016/S0021-9258(18)70884-3

Elion, 1964, Binding of substrates and inhibitors to xanthine oxidases from different species

Rundles, 1963, Effects of a xanthine oxidase inhibitor on thiopurine metabolism, hyperuricemia and gout, Tr. A. Am. Physicians, 76, 126

Elion, 1954, The fate of 6-mercaptopurine in mice, 60, 297

Elion, 1963, Potentiation by inhibition of drug degradation: 6-substituted purines and xanthine oxidase, Biohem. Pharmacol., 72, 85, 10.1016/0006-2952(63)90012-1

Elion, 1963, Relationship between metabolic fates and antitumor activities of thiopurines, Cancer Res., 23, 1207

Wyngaarden, 1963, Control of hyperuricemia with hydroxypyrazolopyrimidine, a purine analogue which inhibits uric acid synthesis, Arthritis & Rheumat., 6, 306

Klinenberg, 1963, The effectiveness of a xanthine oxidase inhibitor in the treatment of gout, Arthritis & Rheumat., 6, 779

Rundles, 1964, Effects of xanthine oxidase inhibitor on clinical manifestations and purine metabolism in gout, Ann. Int. Med., 60, 717, 10.7326/0003-4819-60-4-717_2

Gutman, 1963, The search for uricosuric agents suited to the management of tophaceous gout, New York State J. Med., 63, 576

Sirota, 1952, Effect of benemid (p-(di-n-propylsulfamyl]-benzoic acid) on urate clearance and other discrete renal functions in gouty subjects, J. Clin. Invest., 31, 692, 10.1172/JCI102651

Burns, 1957, A potent new uricosuric agent, the sulfoxide metabolite of the phenylbutazone analogue, G-25671, J. Pharmacol. Exper. Therap., 119, 418

Gutman, 1963, Gout

Gutman, 1953, Primary and secondary gout, Ann. Int. Med., 39, 1062, 10.7326/0003-4819-39-5-1062

Gutman, 1956, The concept of secondary gout; relation to purine metabolism in polycythemia and myeloid metaplasia, Trans. A. Am. Physicians, 69, 229

Praetorius, 1949, An enzymatic method for the determination of uric acid by ultraviolet spectrophotometry, Scandinv. J. Clin. & Lab. Invest., 1, 222, 10.3109/00365514909069945

Weissmann, 1957, The purine bases of human urine II. Semiquantitative estimation and isotope incorporation, J. Biol. Chem., 224, 423, 10.1016/S0021-9258(18)65041-0

Gutman, 1957, Renal function in gout. With a commentary on the renal regulation of urate excretion, and the role of the kidney in the pathogenesis of gout, Am. J. Med., 23, 600, 10.1016/0002-9343(57)90231-0

Gutman, 1963, Urate urolithiasis in primary and secondary gout, Ann. Int. Med., 58, 741, 10.7326/0003-4819-58-4-741_4

Goldfinger, 1964, The renal excretion of oxypurines, Clin. Res., 12, 252

McCollister, 1964, Pseudofeedback inhibition of purine synthesis of 6-mercaptopurine ribonucleotide and other purine analogues, J. Biol. Chem., 239, 1560, 10.1016/S0021-9258(18)91353-0

Pomales, 1963, Augmentation of the incorporation of hypoxanthine into nucleic acids by the administration of an inhibitor of xanthine oxidase, Biochem. et biophys. acta, 72, 119, 10.1016/0926-6550(63)90320-7

Elion, G. B. Personal communication.

Wyngaarden, 1960, Gout

Gutman, 1963, An abnormality of glutamine metabolism in primary gout, Am. J. Med., 35, 820, 10.1016/0002-9343(63)90244-4

Grayzel, 1960, Suppression of uric acid synthesis in the gouty human by the use of 6-diazo-5-oxo-l-norleucine, J. Clin. Invest., 39, 447, 10.1172/JCI104057

Delbarre, 1963, Traitement de la goutte par l'acide uracil-6-carboxylique et ses dérivés, Presse méd., 71, 1765

Gutman, 1952, Current principles of management in gout, Am. J. Med., 13, 744, 10.1016/0002-9343(52)90374-4

Bray, R. C. Xanthine oxidase. In: The Enzymes, 2nd ed. vol. 7. Edited by Boyer, P. D., Lardy, H. and Myrbäck, K. Academic Press, New York.

Mazur, 1958, Mechanism of release of ferritin iron in vivo by xanthine oxidase, J. Clin. Invest., 37, 1809, 10.1172/JCI103774

Dickinson, 1959, Xanthinuria, Brit. M. J., 2, 1217, 10.1136/bmj.2.5161.1217

Engelman, 1964, Clinical, physiological and biochemical studies of a patient with xanthinuria and pheochromocytoma, Am. J. Med., 37, 839, 10.1016/0002-9343(64)90128-7

Ayvasian, 1964, Xanthinuria and hemochromatosis, New England J. Med., 270, 18, 10.1056/NEJM196401022700104

1964, New England J. Med., 270, 53

Hitchings, 1613, Summary of informal discussion on the role of purine antagonists, Cancer Res., 23, 1218